

2022

英文論文

1. 2022 Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, **Kudo M**, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B: Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. **Lancet Oncol** 23:77-90, 2022(IF=54.433).
2. 2022 Aoki T, Nishida N, **Kudo M**: Current perspectives on the Immunosuppressive niche and role of fibrosis in hepatocellular carcinoma and the development of anti-tumor Immunity. **J Histochem Cytochem** 70:53-81, 2022(IF=4.137).
3. 2022 Aoki T, Nishida N, **Kudo M**: Clinical significance of the duality of Wnt/ β -catenin signaling in human hepatocellular carcinoma. **Cancers** 14:444, 2022(IF=6.575). doi: 10.3390/cancers14020444
4. 2022 Yamagishi S, Doman K, Mekada Y, Nishida N, **Kudo M**: Detection and tracking of liver tumors for ultrasound diagnostic support using deep learning. **Journal of Image and Graphics (JOIG)** 10:50-55, 2022(IF=0.000). doi: 10.18178/joig.10.1.50-55
5. 2022 Minaga K, Takenaka M, **Kudo M**: Endoscopic ultrasound-guided biliary drainage with a 22-gauge needle and a 0.018-inch guidewire: Can it be the new standard? **Digest Endosc** 34:79-81, 2022(IF=6.337).
6. 2022 **Kudo M***: Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma. **Liver Cancer** 11:1-8, 2022(IF=12.430).
7. 2021 Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato

英文論文

- M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, **Kudo M**, JSUM AI investigators: Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. **J Gastroenterol** 57:309-321, 2022(IF=6.772).
8. 2022 Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, **Kudo M**: Randomized phase 3 LEAP-012 study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. **Cardiovasc Intervent Radiol (CVIR)** 45:405-412, 2022 (IF=2.740).
9. 2022 Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, **Kudo M**, Breder V, Merle P, Kaseb A, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS: Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. **J Hepatol** 76:862-873, 2022(IF=30.083).
10. 2022 **Kudo M***, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012–2013). **Hepatol Res** 52:5-66, 2022(IF=4.942).
11. 2022 Sakurai T, De Velasco M, Sakai K, Nagai T, Nishiyama H, Hashimoto K, Uemura H, Kawakami H, Nakagawa K, Ogata H, Nisho K, **Kudo M**: Integrative analysis of gut microbes and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. **Mol Oncol** 16:1493-1507, 2022(IF=7.449).
12. 2022 Takenaka M, Rehani MM, Hosono M, Yamazaki T, Omoto S, Minaga K, Kamata K, Yamao K, Hayashi S, Nishida T, **Kudo M**:

2022

英文論文

Comparison of radiation exposure between endoscopic ultrasound-guided hepaticogastrostomy and hepaticogastrostomy with antegrade stenting. **J Clin Med** 11:1705, 2022(IF=4.964).

13. 2022 **Kudo M***, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Nouse K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response evaluation criteria in cancer of the liver (version 6) (RECICL 2021 revised version). **Hepatol Res** 52:329-336, 2022(IF=4.942).
14. 2022 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, **Kudo M**: Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria -Multicenter analysis. **Hepatol Res** 52:308-316, 2022(IF=4.942).
15. 2022 Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Park AM, Sato M, Kawada A, Nakano H, Nakagawa H, **Kudo M**: Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria. **Sci Rep** 12:6100, 2022(IF=4.996).
16. 2022 Otsuka Y, Kamata K, Hyodo T, Chikugo T, Hara A, Tanaka H, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Takenaka M, Chiba Y, Watanabe T, Nakai Y, Matsumoto I, Takeyama Y, **Kudo M**: Utility of contrast-enhanced harmonic endoscopic ultrasonography for T staging of patients with extrahepatic bile duct cancer. **Surg Endosc** 36:3254-3260, 2022(IF=4.584).

2022

英文論文

17. 2022 Minaga K, Watanabe T, Kamata K, **Kudo M**, Strober W: A mouse model of acute and chronic pancreatitis. **Curr Protoc** 2:e422, 2022(IF=0.000).
18. 2022 **Kudo M***: Durvalumab plus tremelimumab: A novel combination Immunotherapy for unresectable hepatocellular carcinoma. **Liver Cancer** 11:87-93, 2022(IF=12.430).
19. 2022 Minami Y, Takaki H, Yamakado K, **Kudo M**: How compatible are immune checkpoint inhibitors and thermal ablation for liver metastases? **Cancers** 14:2206, 2022(IF=6.575). doi.org/10.3390
20. 2022 Chan HLY, Vogel A, Berg T, de Toni E, **Kudo M**, Trojan J, Weinmann A, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V, Lisy MR, Piratvisuth T: Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. **JGH Open**:292-300, 2022(IF=0.320). doi:10.1002/jgh3.12720
21. 2022 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohma H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, **Kudo M**: C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. **Sci Rep** 12:8421, 2022(IF=4.996). doi: 10.1038/s41598-022-12058-y
22. 2022 Omoto S, Takenaka M, Maluf-Filho F, **Kudo M**: A novel and effective EUS training program that enables visualization of the learning curve: Educational Program of Kindai system (EPOK) (with video). **VideoGIE** 7:165-168, 2022(IF=0.710).

2022

英文論文

23. 2022 Masaki S, Watanabe T, Arai Y, Sekai I, Hara A, Kurimoto M, Otsuka Y, Masuta Y, Yoshikawa T, Takada R, Kamata K, Minaga K, Yamashita K, **Kudo M**: Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4. **Clin Exp Immunol** 207:340-350, 2022(IF=5.732).
24. 2022 Tanaka H, Kamata K, Ishihara R, Handa H, Otsuka Y, Yoshida A, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Takenaka M, Watanabe T, Nishida N, **Kudo M**: Value of artificial intelligence with novel tumor tracking technology in the diagnosis of gastric submucosal tumors by contrast-enhanced harmonic endoscopic ultrasonography. **J Gastroenterol Hepatol** 37:841-846, 2022(IF=4.369).
25. 2022 **Abou-Alfa G[†], Lau G[†], Kudo M[†], Chan SL[†]**, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV, De Toni E, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle P, Ali S, Marcovitz M, Makowsky M, Pharm D, He P, Kurland JF, Negro A, Sangro B: Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. **New Engl J Med Evidence**, 2022(IF=0.000). (†Shared 1st authors) DOI: 10.1056/EVIDoa2100070
26. 2022 Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattani S, Blanc JF, Lee KH, Maur M, Pant S, **Kudo M**, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillen-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Myers A, Delord JP: A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or Biomarker-selected solid tumors. **J Exp Clin**

2022

英文論文

Cancer Res 41:189, 2022(IF=4.942).

<https://doi.org/10.1186/s13046-022-02383-5>

27. 2022 Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. **Hepatol Res** 52: 773-783, 2022(IF=4.942).
28. 2022 Watanabe T, Minaga K, Hara A, Yoshikawa T, Kamata K, **Kudo M**: Case report: New-onset rheumatoid arthritis following COVID-19 vaccination. **Front Immunol** 13:859926, 2022(IF=8.786). doi: 10.3389/fimmu.2022.859926
29. 2022 Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Pathel RS, **Kudo M**, Nishida N, Saeed A, Hildebrand H, Kaseb A, Abugabal Y, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron TU: Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. **J ImmunoTher Cancer** 10:e004205, 2022(IF=12.487). doi: 10.1136/jitc-2021-004205
30. 2022 **Kudo M***: New treatment paradigm with systemic therapy in Intermediate-stage hepatocellular carcinoma. **Int J Clin Oncol** 27:1110-1119, 2022(IF=3.850).
31. 2022 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T,

英文論文

- Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Kaseb A, Huang YH, Ang C, **Kudo M**, Nishida N, Personeni N, Rimassa L, Pinato DJ: Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in hepatocellular carcinoma. **Hepatol Commun** 6:1776-1785, 2022(IF=5.701). doi.org/10.1002/hep4.1927
32. 2022 Verset G, Borbath I, Karwal M, Verslype C, Van Vierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattan S, **Kudo M**, Cheng AL, Ogasawara S, Daniele B, Chan S, Finn R, Knox J, Qin SK, Siegel A, Chisamore M, Hatogai K, Wang A, Zhu A: Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial. **Clin Cancer Res** 28:2547-2554, 2022(IF=13.801).
33. 2022 Kamata K, Kinoshita M, Kinoshita I, Imai H, Ogura T, Matsumoto H, Minaga K, Chiba Y, Takenaka M, **Kudo M**, Kitano M: Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer associated pain: A multicenter prospective trial. **Int J Clin Oncol** 27:1196-1201, 2022(IF=3.850).
34. 2022 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hondo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S,

英文論文

- Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsushashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagohori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, **Kudo M**, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M: AJM300 (carotegrast methyl), an oral antagonist of α 4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. **Lancet Gastroenterol Hepatol** 7:648-657, 2022(IF=45.042).
35. 2022 Morimoto D, Hyodo T, Takenaka M, Matsukubo Y, Numoto I, Itoh M, Ohmi M, Kamata K, Ueda Y, Wakana M, **Kudo M**, Saito S, Ishii K: Comparison between gradient and spin-echo (GRASE) and compressed sensing sequences for single breath-hold three-dimensional magnetic resonance cholangiopancreatography in patients with T1 hyperintense bile. **Eur J Radiol** 150:110279, 2022(IF=4.531). doi: 10.1016/j.ejrad.2022.110279
36. 2022 **Kudo M**, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX, on behalf of the KEYNOTE-224 Investigators: Updated efficacy and safety of KEYNOTE-224: a phase 2 study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. **Eur J Cancer** 167:1-12, 2022(IF=10.002). doi: 10.1016/j.ejca.2022.02.009
37. 2022 Llovet JM, Singal AG, Villanueva A, Finn RS, **Kudo M**, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau

2022

英文論文

- RC, Gonzalez-Gugel E, Zhu AX: Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trials. **Clin Cancer Res** 28:2297-2305, 2022(IF=13.801).
38. 2022 Takayama T, Hasegawa K, Izumi N, **Kudo M**, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, Tateishi R, Shiina S, Koike K, Matsuyama Y, Omata M, Makuuchi M, Kokudo N: Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF-trial). **Liver Cancer** 11:209-218, 2022(IF=12.430).
39. 2022 **Kudo M***: Selection of systemic treatment regimen for unresectable hepatocellular carcinoma: Does etiology matter? **Liver Cancer** 11:283-289, 2022.
40. 2022 Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, Itoi T, Unno M, Ohtuka M, Okusaka T, Kadoya M, **Kudo M**, Kumada T, Kokudo N, Sakamoto M, Sakurai H, Takayama T, Nakashima O, Nagata Y, Hatano E, Harada K, Murakami T, Yamamoto M: Liver Cancer Study Group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma. **Liver Cancer** 11:290-314, 2022(IF=12.430).
41. 2022 **Kudo M***[†], **Ueshima K**[†], Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y: Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. **Liver Cancer** 11:354-367, 2022(IF=12.430). ([†]Shared 1st authors)

2022

英文論文

42. 2022 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohma H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, **Kudo M**: Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. **Eur J Gastroenterol Hepatol** 34:857-864, 2022(IF=2.586).
43. 2022 Tanaka H, Minaga K, Otsuka Y, Masuta Y, Kamata K, Yamao K, Takenaka M, Hyodo T, Kimura M, Watanabe T, **Kudo M**: Pancreatic neuroendocrine carcinoma with unique morphological features mimicking intraductal papillary mucinous carcinoma: A case report. **Front Med** 9:951834. doi: 10.3389/fmed.2022.951834(IF=5.058).
44. 2022 Okamoto A, Kamata K, Miyata T, Yoshikawa T, Ishikawa R, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Takenaka M, Chiba Y, Sakurai T, Nishida N, Kitano M, **Kudo M**: Bispectral index-guided propofol sedation during endoscopic ultrasonography. **Clin Endosc** 55:558-563, 2022(IF=0.470).
45. 2022 Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, **Kudo M**, Koike K: Current status of primary liver cancer and decompensated cirrhosis in Japan: Launch of a nationwide registry for advanced liver diseases (REAL). **J Gastroenterol** 57:587-597, 2022(IF=6.772).
46. 2022 Takenaka M, **Kudo M**: What is the most appropriate diagnostic strategy for evaluating a small common bile duct stone? **Digest Endosc** 34:1060-1062, 2022(IF=6.337).

2022

英文論文

47. 2022 Masuta Y, Watanabe T, Minaga K, **Kudo M**: A case of ulcerative colitis relapse characterized by systemic type I interferon responses after COVID-19 vaccination. **Inflamm Bowel Dis** 28:e110-e111, 2022(IF=7.290).
48. 2022 Masuta Y, Watanabe T, Minaga K, **Kudo M**: Reply to response to “A case of ulcerative colitis relapse characterized by systemic type I interferon responses after COVID-19 vaccination” by Mungmunpuntipantip et al. **Inflamm Bowel Dis** 28:e113, 2022(IF=7.290). doi: 10.1093/ibd/izac081.
49. 2022 Takenaka M, **Kudo M**: Endoscopic reintervention for recurrence of malignant biliary obstruction: Developing the best strategy. **Gut Liver** 16:525-534, 2022(IF=4.321).
50. 2022 Otsuka Y, Kamata K, Minaga K, Watanabe T, **Kudo M**: Pancreatic colonization of fungi in the development of severe acute pancreatitis. **Front Cell Infect Microbil** 12:940532, 2022(IF=6.073). doi: 10.3389/fcimb.2022.940532.
51. 2022 **Kudo M***: Combination immunotherapy with anti-PD-1/PD-L1 antibody plus anti-VEGF antibody may promote cytotoxic T lymphocyte infiltration in hepatocellular carcinoma, including in the non-inflamed subclass. **Liver Cancer** 11:185-191, 2022(IF=12.430).
52. 2022 Okusaka T, **Kudo M**, Ikeda K, Ikeda M, Okita K, Sugawara M, Tamai T, Ren M, Saito K, Kumada H: Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma. **Hepatol Res** 52:784-793, 2022(IF=4.942).
53. 2022 Okai N, Watanabe T, Minaga K, Kamata K, Honjo H, **Kudo M**: Alterations of autophagic and innate immune responses by the Crohn’s disease-associated ATG16L1 mutation. **World J Gastroenterol** 28:3063-3070, 2022(IF=5.374).

2022

英文論文

54. 2022 **Kudo M***: Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. **Hepatobil Surg Nutr** 11:592-596, 2022(IF=8.265).
55. 2022 Minaga K, **Kudo M**: Connected or disconnected: What's next after successful transmural drainage of pancreatic fluid collection? **Digest Endosc** 34:1242-1244, 2022(IF=6.337).
56. 2022 Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, **Kudo M**: Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. **Hepatol Res** 52:754-761, 2022(IF=4.942).
57. 2022 Hagiwara S, Yoshida T, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, **Kudo M**: Progression from early to advanced stage of immune-related cholangitis. **Hepatol Res** 52:888-892, 2022(IF=4.942).
58. 2022 Minami Y, Aoki T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M**: Prognostic factors for overall survival in patients with HCV-Related HCC undergoing molecular targeted therapies: beyond a sustained virological response. **Cancers** 14: 4850, 2022(IF=6.575).
59. 2022 Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, Tanaka T, Matsueda K, Moriguchi M, Saito H, Sone M, Yamagami T, Inaba Y, **Kudo M**, Arai Y: Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of implantable port assisted treatment. **Liver Cancer** 11:407-425, 2022(IF=12.430).
60. 2022 **Kudo M***: Atezolizumab plus bevacizumab followed by curative

2022

英文論文

conversion (ABC conversion) in patients with unresectable, TACE-unsuitable Intermediate-stage hepatocellular carcinoma. **Liver Cancer** 11:399-406, 2022(IF=12.430).

61. 2022 Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, **Kudo M**, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ: Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. **Eur J Cancer** 175:204-213, 2022(IF=10.002).
62. 2022 Takenaka M, **Kudo M**: Usefulness of the double-guidewire technique for endoscopic procedures in the field of biliary and pancreatic diseases. **Clin Endosc** 55:605-614, 2022(IF=0.470).
63. 2022 Takenaka M, **Kudo M**: How should a therapeutic strategy be constructed for acute cholecystitis after self-expanding metal stent placement for malignant biliary obstruction? **Clin Endosc** 55:757-759, 2022(IF=0.470).
64. 2022 Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, **Kudo M**, Rimassa L, Pinato DJ, Sharma R: Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. **Liver Int** 42:2538-2547, 2022(IF=8.754).
65. 2022 Omaru N, Watanabe T, Kamata K, Minaga K, **Kudo M**:

英文論文

- Activation of NOD1 and NOD2 in the development of liver injury and cancer. **Front Immunol** 13:1004439, 2022(IF=8.786).
66. 2022 Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Alrighetti L, **Kudo M**, Cascinu S, Casadei-Gardini A: Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. **ESMO Open** 7:100591, 2022(IF=6.883).
67. 2022 Miyawaki K, Komori T, Ishida Y, Sakaguchi Y, Honjo H, **Kudo M**, Otsua A: Cronkhite-Canada syndrome mimicking COVID-19-related symptoms. **Acta Derm-Venereol** 102:adv00812, 2022(IF=3.875). doi: 10.2340/actadv.v102.3402
68. 2022 Hagiwara S, Komeda Y, Nishida N, Yoshida A, **Kudo M**: A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. **Cancer Rep** 5:e1721, 2022(IF=0.210). doi: 10.1002/cnr2.1721
69. 2022 Masaki S, Komeda Y, Yoshioka Y, Takenaka M, **Kudo M**: Endoscopic submucosal dissection with reinforcement using a laparoscopic approach (D-LECS with ESD) for a duodenal

2022

英文論文

- cavernous hemangioma. **VideoGIE** 7:392-394, 2022(IF=0.710).
70. 2022 Sekai I, Minaga K, Hara A, Kurimoto M, Omaru N, Okai N, Otsuka Y, Masuta Y, Takada R, Yoshikawa T, Kamata K, **Kudo M**, Watanabe T: High-fat diet aggravates experimental autoimmune pancreatitis through the activation of type I interferon signaling pathways. **Biochem Bioph Res Commun** 637:189-195, 2022(IF=3.322).
71. 2022 Nakai A, Kamata K, Hyodo T, Chikugo T, Hara A, Otsuka Y, Tanaka H, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Omoto S, Minaga K, Yamao K, Takenaka M, Chiba Y, Watanabe T, Matsumoto I, Takeyama Y, **Kudo M**: Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. **Endosc Ultrasound** 11:401-406, 2022(IF=5.275).
72. 2022 Takenaka M, Fukunishi K, Takashima K, Yamazaki T, **Kudo M**: Efficacy of an easy loop-forming guidewire in endoscopic transpapillary gallbladder drainage for gallstones impacted in the cystic duct. **Endoscopy** 54:E1078-E1080, 2022(IF=9.776).
73. 2022 Tekanaka M, Fukunaga T, Yoshida A, Omoto S, **Kudo M**: The "straighten pigtail" technique for selective replacement of a pigtail plastic stent. **Endoscopy** 54:E1083-E1085, 2022(IF=9.776).
74. 2022 Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, **Kudo M**, Kawaguchi T, Hatanaka T, Nouse K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A: Validation of the easy-to-use Lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma

2022

英文論文

patients treated with Lenvatinib. **Hepatol Res** 52:1050-1059, 2022(IF=4.942).

75. 2022 Kim SK, Fujii T, Kim SR, Lim YS, Hagiwara S, **Kudo M**: Hepatitis B virus treatment and hepatocellular carcinoma - controversies and approaches to consensus. **Liver Cancer** 11:497-510, 2022(IF=12.430).
76. 2022 **Kudo M***: Implications of the TACTICS trial: Establishing the new concept of combination/sequential systemic therapy and TACE to achieve synergistic effects. **Liver Cancer** 11:487-496, 2022(IF=12.430).
77. 2022 Casadei-Gardini A, Rimini M, **Kudo M**, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S: REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study. **Liver Cancer** 11:527-539, 2022(IF=12.430).
78. 2022 Li D, Toh HC, Merle P, Tsuchiya K, Harnandez S, Verret W, Nicholas A, **Kudo M**: Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in the IMbrave150 randomized clinical trial. **Liver Cancer** 11:558-571, 2022(IF=12.430).
79. 2022 Takenaka M, Omoto S, **Kudo M**: EUS-guided drainage of the gallbladder using a novel 0.018-inch guidewire for preventing bile leakage (with video). **Endosc Ultrasound** 11:520-521, 2022(IF=5.275).
80. 2022 Minaga K, Kitano M, Uenoyama Y, Hatamaru K, Shiomi H, Ikezawa K, Miyagahara T, Imai H, Fujimori N, Matsumoto H, Shimokawa Y, Masuda A, Takenaka M, **Kudo M**, Chiba Y:

英文論文

- Feasibility and efficacy of endoscopic reintervention after covered metal stent placement for EUS-guided hepaticogastrostomy: a multicenter experience. **Endosc Ultrasound** 11:478-486, 2022(IF=5.275).
81. 2022 Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, **Kudo M**, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato D, Ang C: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. **Cancers** 14:5834, 2022(IF=6.575). doi: 10.3390/cancers14235834
82. 2022 **Kudo M***, Montal R, Finn R, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM: Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies. **Clin Cancer Res** 28:3443-3451, 2022(IF=13.801).
83. 2023 Yoshikawa T, Minaga K, Hara A, Sekai I, Kurimoto M, Masuta Y, Otsuka Y, Takada R, Kamata K, Park AM, Takamura S, **Kudo M**, Watanabe T: Disruption of intestinal barrier exacerbates experimental autoimmune pancreatitis by promoting translocation of staphylococcus sciuri into pancreas. **Int Immunol** 34:621-634, 2023 (IF=5.071).
84. 2022 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsi A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M,

2022

英文論文

Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, **Kudo M**:
Clinical predictor of urinary protein as adverse event associated
with atezolizumab plus bevacizumab treatment for unresectable
hepatocellular carcinoma. **Oncology** 100:645-654,
2022(IF=3.734).